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Abstract: Owing to their nano-sized porous structure, CaCO3 nanocrystals (CaCO3NCs) hold the
promise to be utilized as desired materials for encapsulating molecules which demonstrate wide
promise in drug delivery. We evaluate the possibility to encapsulate and release NVP-BEZ235, a novel
and potent dual PI3K/mTOR inhibitor that is currently in phase I/II clinical trials for advanced solid
tumors, from the CaCO3NCs. Its chemical nature shows some intrinsic limitations which induce to
administer high doses leading to toxicity; to overcome these problems, here we proposed a strategy to
enhance its intracellular penetration and its biological activity. Pristine CaCO3 NCs biocompatibility,
cell interactions and internalization in in vitro experiments on T-cell lymphoma line, were studied.
Confocal microscopy was used to monitor NCs-cell interactions and cellular uptake. We have further
investigated the interaction nature and release mechanism of drug loaded/released within/from the
NCs using an alternative approach based on liquid chromatography coupled to mass spectrometry.
Our approach provides a good loading efficiency, therefore this drug delivery system was validated
for biological activity in T-cell lymphoma: the anti-proliferative test and western blot results are very
interesting because the proposed nano-formulation has an efficiency higher than free drug at the
same nominal concentration.
Keywords: CaCO3 nanocrystals; NVP-BEZ235; mass spectrometry; T-cell lymphoma; drug delivery; nanomedicine
1. Introduction
The main limit of anticancer drugs is the crossing of cell membranes; in particular, hydrophobic
drug prefer to stay in the double lipid layer, whilst the polar drug molecules prefer to reach the aqueous
cytoplasm environment. Furthermore, it’s known that low concentrations of drugs in the target tissues
will lead to suboptimal therapeutic effects and require more frequent administrations; on the other
hand, high drug concentrations might not be tolerated and could cause toxicity [1].
Cancers 2018, 10, 31; doi:10.3390/cancers10020031 www.mdpi.com/journal/cancers
Cancers 2018, 10, 31 2 of 16
In this regard, the advent of nanomaterials provides an efficient mechanism for more convenient,
controlled and targeted drug delivery, which is interesting in terms of application in the biomedical
field, since they have a large effectiveness [2].
The importance of drug delivery has increased over the past decades, and significant advances
have been made in the development of novel technologies. In order to create an ideal nano-carrier,
considerable effort has been spent to make “soft” drug carriers, such as liposomes, micelles, dendrimers,
and biodegradable polymers [3,4]. Beside them, inorganic nanomaterials have many fundamental
advantages due to the ease of synthesis and modification [5].
Here, the use of calcium carbonate nanocrystals (CaCO3 NCs), obtained according to our
patented protocol [6], was suggested as template in order to encapsulate a poorly water-soluble
drug, NVP-BEZ235. The special properties of this novel material have been used in the biomedical
communities with the hope of developing a new drug delivery system for therapeutic treatment
agents such as proteins, nucleic acids, and other biologically active molecules [7–11], owing to
their reduced toxicity effects due to their small size, stable structures phase, specific surface area,
chemical purity, safety, biocompatibility, pH-sensitivity and slow biodegradability [12–14]. Given the
potential abilities of CaCO3NCs to reach the intracellular compartment, the potential application
of CaCO3NCs is used for transport and delivery of drugs and antibodies without toxic effects.
This material is considered as an ideal drug carrier thanks to the excellent biocompatibility, targeting
action, and subcellular localization.
For example, in a recent work, CaCO3 NCs were proposed as a pH-responsive carrier for
delivery of chemotherapeutics or nucleic acids because it is stable under neutral pH and would be
decomposed into Ca2+ and CO2 under acidic pH [15,16]. Zhao et al. reported that CaCO3 nanospheres
loaded with doxorubicin exhibited greatly enhanced therapeutic effects over the free drug towards
tumor cells [17]. In another research work, core shell CaCO3 nanoparticles loaded with doxorubicin,
were used for in vivo liver cancer chemotherapy [18]. Furthermore, recently they were used as powerful
stimuli-responsive nano-theranostics tools for simultaneously enhancing the accuracy and efficiency of
cancer therapies [16]. There is a lot of room to explore CaCO3 micro- and nanoparticles in combination
with additives or other materials such as polymers, surfactants, liposomes and micelles [19].
The majority of the available pharmaceutical anticancer drugs are hydrophobic in nature and
there is an urgent need to develop a selective delivery system for these drugs. Lately, novel composite
cyclodextrin—CaCO3 spherical porous microparticles have been synthesized to deliver hydrophobic
drug [20]. The strategy proposed here could be useful to enhance the bioavailability of many insoluble
drugs, considering that approximately 60–70% of the drug molecules are insufficiently soluble in
aqueous media and/or have very low permeability [21].
NVP-BEZ235, an imidazo[4,5-c]quinoline derivative, efficiently blocks the dysfunctional activation
of the PI3K/mTOR pathway in cellular and in vivo settings, thus inhibiting the growth and
proliferation of various cancer cells [22,23]. The PI3k/Akt/mTOR pathway controls gene expression
related to cell proliferation, differentiation and apoptosis [24]. The prevalence of PI3K signaling
abnormalities in human cancer cells has suggested the potential use of PI3K pathway modulators as
novel targeted therapeutic agents. Over the past few years, the interests of pharmaceutical chemistry
have been directed to develop pan- or isoform-selective PI3K inhibitors with improved pharmacologic
characteristics as well as selectivity profile [25,26].
Its very poor solubility in water and ethanol has caused difficulty in managing the variable
NVP-BEZ235 toxicity in trials beyond phase I/Ib [27]. Carrier-based drug delivery is a promising
approach to improve the bioavailability while at the same time providing the necessary protection of
drug molecules [28].
As most cancer environments exhibit a lower pH than healthy tissues, the pH value-sensitive
feature of CaCO3 can stably preserve drugs under physiological conditions and selectively release
them in the acidic intracellular tumor environment [29–31]. When the CaCO3 NCs accumulate at the
tumor site through the enhanced permeability and retention (EPR) effect, a fast and stable drug release
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can be triggered in response to extracellular or intracellular stimulus of tumor cells, where pH value
is lower than that in the normal tissue. The liquid tumor microenvironment, like the here proposed
model, have a constant pH gradient closer to the normal tissue, but a saturated solution of CaCO3
has a predicted pKa of about 9, suggesting a slow but constant tendency to dissolution [15]. In the
present work, we propose the use of pure CaCO3NCs, to deliver NVP-BEZ235, in order to enhance its
solubility, penetration and efficacy in T-cell lymphoma HUT78 cell line.
As already described in previous works, we synthesized this nanomaterial using the spray drying
technique, which may be easily usable on a large scale system. Despite the common multi-parametric
nanosynthesis the here-adopted process was easily reproducible with a commercial spray dryer
(Mini Spray Dryer B-290, Büchi, Milan, Italy) and ready to be scaled up on an industrial plant [6].
In this work, we demonstrated that these CaCO3NCs readily penetrate in T-cell lymphoma,
and the nano-formulation with NVP-BEZ235 is more efficient, in term of cytotoxicity and
biological response, over the same nominal concentration of free drug. Biological activity of
encapsulated NVP-BEZ235 increased with the same trend of its solubility, loading efficiency and
intracellular penetration.
Thanks to this strategy we have greatly improved the bioavailability and the membrane
permeability of the drug within the cell, as demonstrated with the analytical data concerning the
determination of the effective intracellular concentration of the drug.
For this purpose, an approach based on liquid chromatography coupled to mass spectrometry
was adopted to quantify the drug loaded inside NCs, inside cytoplasm, or entrapped in the
membrane [32]. This method is convenient compared to other conventional ones that are mostly
based on fluorescence [33].
Liquid chromatography/tandem mass spectrometry (LC-MS/MS) is a very sensitive method
with limits of detection in the femtomolar range when operating in selected reaction monitoring mode
(SRM). A new developed LC-MS/MS method was herein applied to demonstrate that NVP-BEZ235,
because of its lipophilicity, remains trapped in the cell membrane, not succeeding in performing its
pharmacological action. In the case of nano-formulation (CaCO3 NCs-NVP-BEZ235) the drug is easily
available to exert its bioactivity in the cytosolic environment, where its biological target is localized.
2. Results and Discussion
2.1. Nanocrystals Synthesis and Characterization
CaCO3 NCs were synthesized according to the literature, as described in the Materials and
Method section [6,9]. The preparation technique adopted herein allows one to obtain stable calcite
nanocrystals which are very advantageous since they do not provoke adverse cellular reactions and
do not block the normal cell cycle [34]. CaCO3 NCs have an ellipsoidal shape and in order to study
their size, together with Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS)
measurements (summarized in Table 1) [9], nanoparticle tracking analysis (NTA) was also performed
by means of a Nanosight instrument (Malvern, Worcestershire, UK). High resolution particle size,
concentration and aggregation measurements under Brownian motion of the NCs suspensions were
measured in order monitor in real time the subtle changes in the characteristics of particle populations.
The results on size distribution are summarized in Figure 1. CaCO3 NCs have a dimension of about
76.1± 0.9 nm.
Table 1. Size measurements [9].
TEM Measurement (nm) DLS Measurement (nm) ζ-Potential Measurement (mVolt)
Major diameter 93 ± 9 UP water: 222.7 ± 9.2 UP water: 6.8 ± 0.1
Minor diameter 35 ± 10 PBS: 188.8 ± 4.4 PBS: −25.1 ± 0.3Culture media: 344.0 ± 32.8 Culture media: −11.2 ± 0.2
TEM, Transmission Electron Microscopy; DLS, Dynamic Light Scattering.
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DLS: Dynamic Light Scattering the size measurements were performed at different time
point for up to 6 weeks, obtaining always the same results. This result together with ζ-potential
measurements suggest that the spray drying synthesis procedure allows to obtain a stable
dispersion in water. Furthermore, the Nanosight device provided data about the concentration
of CaCO3 nanocrystals. In our samples the mean of nanocrystals in 1 mL of ultra-pure water was:
5.54 × 109 ± 3.30 × 108 particles/mL.
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2.2. Loading of NVP-BEZ235 into CaCO3 NCs
The porous morphology of CaCO3 is useful to entrap macromolecules efficiently by physical
adsorption due to their large surface area [35–37]. The loading protocol, as described in the Materials
and Methods in Section 3.4, was performed using two different final concentration of the drug: 1 µM
and 100 µM. The adsorption of NVP-BEZ235 occurred in the core interstices of CaCO3 nanocrystals
due to their porous structure: one can argues that the core acts like a sponge that absorbs a proportional
amount of drug respect to the solution with whom it comes into contact. The % loading was calculated
as reported in the Materials and Methods in Section 3.4. The results indicated that NVP-BEZ235, in both
conditions, was completely encapsulated into carbonate nanocrystals (% loading = 99.8 ± 0.1%).
2.3. Internalization of CaCO3 Nanocrystals in T-Cell Lymphoma Line HUT78
Imaging is a powerful technique for the study of cellular interactions with extracellular substrates,
including particles [38,39]. We investigated the internalization by cells of calcium carbonate particles,
because the goal of this work is the enhancement of cell penetration of NVP-BEZ235. This drug plays
a critical role in the inhibition of PI3K/mTOR pathway competing at its ATP-binding site [40–42].
For this reason, it is important that this molecule crosses the cell membrane reaching the cytoplasmic
region in order to perform its pharmacological action. Being a poorly water-soluble molecule we
thought to deliver it through the CaCO3 NCs. First, we checked whether the nanocrystals were
internalized in this cell line by confocal microscopy.
To study uptake, we used the layer by layer (LbL) technique in order to obtain fluorescent CaCO3
NCs [9]. The polymers used were PSS (polystyrene sulfonate sodium salt) and PAH (polyallyl amine
hydrochloride); only in one of the layers the polyelectrolyte used for coating (labeled as PAH-FITC)
was conjugated with fluorescein moieties.
In particular, the cells were cultured for 5 h with PSS/PAH coated nanocrystals (dosed at a constant
particle mass 1.0 mg/mL) since the synthetic multilayer is not enzymatically degraded by proteases.
Thanks to their nanometric size and positive superficial charge, internalization by T-cell lymphoma
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was in fact observed (Figure 2). To minimize the possible interference of the residual nanocrystals
externally bound to the cells, a PBS solution was used to wash extensively the cells after incubation.Cancers 2018, 10, x  5 of 15 
 
 
Figure 2. Confocal images of a negative control (a), Fluorescein isothiocyanate (FITC)-CaCO3 NCs 
after 5 h (b), and 24 h (c) in HUT78 cells. In blue are stained nuclei and in green CaCO3 NCs. Scale 
bar, 5 µm. 
As shown in Figure 2 fluorescent nanocrystals clearly penetrate the cell membrane and are 
mainly localized in the cytoplasm. No background fluorescence was observed, after long time 
incubation period (Figure 2c). Confocal microscopy results showed that the staining pattern of 
nanocrystals remained the same with a strong fluorescence in the cytoplasm. In particular, no 
fluorescence was observed in extracellular regions, indicating that nanocrystals internalized within 
the cells did not leak. 
2.4. Cytotoxicity Assay  
Biological tests in order to verify the effectiveness of the system were assessed. We studied the 
effects on cell proliferation of 1.0 mg naked CaCO3 NCs, free-NVP-BEZ235 (1 µM) and encapsulated 
NVP-BEZ235 prepared at the final concentration of 1 µM equivalent on T-cell lymphoma line at 
increasing times (from 30 min up to 48 h) by MTT assay. 
In Figure 3 the values represent mean ± SD., and were obtained from three independent 
experiments. The results suggested that encapsulated NVP-BEZ235 was significantly more efficient 
than free-NVP-BEZ235 at the same nominal concentration with a difference statistically significant. 
Naked CaCO3 NCs have no cytotoxic effects. The cell proliferation evidence suggested that our nano-
formulation improved the cell penetration of NVP-BEZ235 leading to an improved biological activity, 
as confirmed by the quantification of drug performed by LC-MS/MS method. 
 
Figure 3. Anti-proliferative effects of naked CaCO3 NC (plain gray bars), free NVP-BEZ235 1 µM 
(black bars) and encapsulated NVP-BEZ235 1 µM equivalent (gray pattern bars) on T-cell lymphoma 
line (HUT78) at different time points. Values represent mean + SD, and were obtained from three 
independent experiments. Statistically significant value p < 0.05 (*) and statistically highly significant 
p < 0.001 (**). 
Figure 2. Confocal images of a negative control (a), Fluorescein isothiocyanate (FITC)-CaCO3 NCs after
5 h (b), and 24 h (c) in HUT78 cells. In blue are stained nuclei and in green CaCO3 NCs. Scale bar, 5 µm.
As shown in Figure 2 fluorescent nanocrystal c early penetra e he c ll me brane and are mainly
localized in the cytoplasm. N b ckground fluorescence was observed, after long time incubation
period (Figure 2c). Confocal microscopy results showed that the staining pattern of nanocrystals
remained the same with a strong fluorescence in the cytoplasm. In particular, no fluorescence was
observed in extracellular regions, indicating that nanocrystals internalized within the cells did not leak.
2.4. Cytotoxicity Assay
Biological tests in order to verify the effectiveness of the system were assessed. We studied the
effects on cell proliferation of 1.0 mg naked CaCO3 NCs, free-NVP-BEZ235 (1 µM) and encapsulated
NVP-BEZ235 pre ared at the final conce trati n of 1 µM equivalent on T-cell lymphoma line at
increasing times (from 30 min up to 48 h) by say.
In Figure 3 the values represent mean ., and w re obtained from three independent
experiments. The results suggested that encapsulated NVP-BEZ235 was significantly more efficient
than free-NVP-BEZ235 at the same nominal concentration with a difference statistically significant.
Naked CaCO3 NCs have no cytotoxic effects. The cell proliferation evidence suggested that our
nano-formulation improved the cell penetration of NVP-BEZ235 leading to an improved biological
activity, as confirmed by the quantification of drug performed by LC-MS/MS method.
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2.5. Quantification of NVP-BEZ235 by LC-MS/MS Method
Free NVP-BEZ235 and encapsulated NVP-BEZ235 (1 µM equivalent) were incubated individually
with a T-cell lymphoma line for 2, 5, 12 and 24 h. Due to the very low concentration of the drug and
the high complexity of the cell lysate matrix, it was important to develop a highly sensitive analytical
method for the detection and quantification of NVP-BEZ235. The choice of the extraction solvent is also
crucial, since it affects the amount of drug extracted. Indeed, we used two different extraction solvents
and compared the results obtained. First, the analyte was extracted from cell lysate with a hypotonic
buffer. Secondly, we performed an extraction with tert-butylmethyl ether (TBME) as described in the
Materials and Methods section. In both experiments internalization kinetics of NVP-BEZ235 in a T-cell
lymphoma line evaluated by LC-MS/MS was consistent with the biological results, which suggested
that nano-encapsulated NVP-BEZ235 was 100 times more efficient than free NVP-BEZ235 (MTT assay).
These findings indicated that the use of CaCO3 NCs dramatically increased the cell permeation of
the drug.
The results obtained by extracting free NVP-BEZ235 and encapsulated-NVP-BEZ235 from cell
lysate with LC-MS/MS mobile phase (acetonitrile:water:formic acid 95:5:0.1 (v/v/v)) are reported in
Figure 4.
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Figure 4. Comparison of intracellular concentrations of NVP-BEZ235 (in the cytosolic fraction)
after exposure of T-cell lymphoma line for 2, 5, 12 and 24 h to the free drug (plain gray)
and nano-encapsulated drug (gray pattern). The bars are plotted as mean and error bars represent the
SD. (n = 3).
The results, shown in Figures 4 and 5, sug ested that the uptake f free NVP-BEZ235 in the cells
occurred in the first hour of incubation. After being stored in vesicles, it l wly diffused in the cytosolic
fraction over the next 24 h, re a concentration of about 0.23 106 cells. On the other hand,
the uptake of nano-encapsulated NVP-BEZ235 in the cytosolic fraction occurred during the first 2 h of
incubation reaching the concentration of about 0.67 nmol/106 cells and remaining quite stable over
about 12 h.
Furthermore, a different LC-MS/MS method was developed to quantify NVP-BEZ235 entrapped
in cell membrane (vesicular fraction). The extraction of NVP-BEZ235 from cell lysate was performed
with TBME, which is able to dissolve not only the cytosol content but also that of the cell membranes.
The same LC-MS/MS analyses were then carried out on these new extracted samples in order to
understand whether the drug is trapped by the membranes. Indeed, the graph of Figure 5 shows that
in the first 2 h free NVP-BEZ235 is mainly concentrated in the cell membrane (0.025 nmol/106 cells).
This is most certainly due to its high lipophilicity.
These findings indicated that CaCO3 NCs allow to overcome the limitation related to
hydrophobicity of this promising drug. These data are confirmed also by western blot assays used
to study the dual inhibition pathway (PI3K/mTOR) elicitated by NVP-BEZ235, explained in the
next section.
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Figure 5. Comparison of vesicular concentrations of NVP-BEZ235 (extracted with TBME) after exposure
of T-cell lymphoma line for 2, 5, 12 and 24 h to the free drug (plain gray) and nano-encapsulated drug
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2.6. Western Blot Analysis
We investigated the effects of 1.0 mg of naked CaCO3 NCs, free-NVP-BEZ235 1 µM and
encapsulated NVP-BEZ235 1 µM equivalent for 5, 12 and 24 h in targeting PI3K/Akt/mTOR pathway
in T-cell lymphoma line. Cellular extracts were probed with antibodies against PI3K, p-Akt (Ser473),
total Akt, p-m-TOR (Ser2448) and total m-TOR (Ser2448). Encapsulated NVP-BEZ235 treatment
affected the phosphorylation status of -Akt and p-m-TOR in time dependent manner (Figure 6a).
The same cellul r extracts were probed with an ibodies against the cleaved form of caspase
3 (Asp175) to evaluate the apoptotic effects of empty capsules, free-NVP-BEZ235 (1 µM) and
encapsulated NVP-BEZ235 (1 µM equivale t) for 5, 12 a d 24 h (Figure 6b).
The encapsulated drug, on the one hand, increases in a time dependent manner the cleaved form
of caspase 3, involved in the apoptotic pathway, and on the other side, decreases the phosphorylation
status of p-Akt, PI3K and p-m-TOR, involved in cell proliferation and differentiation, in a time
dependent manner, more efficiently than the same nominal concentration of free drug. These interesting
results could allow to use clinically a dose of encapsulated drug 100 times lower than the dose of free
drug, obtaining the same results, thus eliminating in this way all the side effects linked to the intrinsic
toxicity of the drug.Cancers 2018, 10, x  8 of 15 
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Figure 6. Western blots of cellular extracts from HUT78 cell line treated with naked CaCO3 NCs,
free NVP-BEZ235 (1 µM) and encapsulated NVP-BEZ235 (1 µM equivalent) for 5, 12 and 24 h.
(a) Lysates were probed with antibodies against the cleaved form of caspase 3 (Asp175); (b) Lysates
were probed with antibodies against PI3K, p-Akt (Ser473), total Akt, p-m-TOR (Ser2448) and total
m-TOR (Ser2448). Densitometric quantification of bands normalized to the untreated control is shown
below the immunoblot bands.
3. Materials and Methods
3.1. Materials and Reagents
The sources of the chemicals are as follows: calcium chloride dehydrate 99.99% (CaCl2·2H2O,
Aldrich, Darmstadt, Germany), sodium hydrogen carbonate (NaHCO3) (pro analysis, Merck, Darmstadt,
Germany), fetal bovine serum (FBS, Sigma, Darmstadt, Germany), penicillin-streptomycin solution
(Sigma), sodium pyruvate (Sigma), RPMI medium (Sigma), thiazolyl blue tetrazolium bromide
≥ 97.5% TLC (Sigma), phosphate buffered saline, Dulbecco A (PBS, Oxoid, Thermo Fisher Scientific,
Waltham, Massachusetts, USA), PSS (polystyrene sulfonate sodium salt, Sigma) and PAH (polyallyl
amine hydrochloride, Sigma). Dimethylsulfoxide (DMSO; Euroclone, Milan, Italy). NVP-BEZ235
was purchased from Selleck Chemicals (Houston, TX, USA). The internal standard (IS) 5-(2,6-di-
4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyridinamine (BKM120) was purchased from Selleck
Chemicals. The cutaneous T-cell lymphoma line HUT78 was purchased from Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (Leibniz-Institute, Germany) and were characterized as specified
(https://www.dsmz.de/research/human-and-animal-cell-lines.html). MTT cellTiter nonradioactive cell
proliferation assay was from Promega Madison (Fitchburg, WI, USA).
3.2. Nanocrystals Synthesis
Pure CaCO3NCs were synthesized by an atomization process, as already described in our recent
paper [9]. Briefly, the synthesis involves the mixing of two aqueous solutions of NaHCO3 and CaCl2
at a 2:1 molar ratio, in atmosphere and temperature-controlled environment. The two solutions are
mixed using two pumps, which allow a fine control of the flow rate of each reagents. Then they are
atomized in a hot air flow at 140 ◦C. The high temperature causes a rapid evaporation of the aqueous
reaction mixture, and allows the direct production of the powder of calcium carbonate and of sodium
chloride, which are accumulated in a collection vessel; the reaction by-product (NaCl) can be easily
removed by means of later water washings.
3.3. Nanocrystals Characterization
The NanoSight NS300 Instrument (Malvern) provides an easy-to-use, reproducible platform for
nanocrystals characterization. The NanoSight NS300 uses the technology of Nanoparticle Tracking
Analysis (NTA). This unique technology utilizes the properties of both light scattering and Brownian
motion in order to obtain the size distribution and concentration measurement of particles in liquid
suspension. All measurements were performed at room temperature. The software used for capturing
and analyzing the data was the NTA 3.1 Build 3.1.46. The samples were measured for 60 s with manual
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shutter and gain adjustments. The error bars displayed on the NTA graphs were obtained by the
standard deviation of five different measurements of each sample. The mean size and SD values
obtained by the NTA software correspond to the arithmetic values calculated with the sizes of all the
particles analyzed by the software.
3.4. Loading of NVP-BEZ235 into CaCO3 Nanocristals
NVP-BEZ235 was dissolved in DMSO to create a 10−2 M stock solution that was stored at −80 ◦C.
The stock solutions were further diluted with cell culture medium to appropriate concentrations before
use. The maximum final concentration of DMSO (<0.1%) did not affect cell proliferation and did
not induce cytotoxicity on the tested cell lines and primary cells (data not shown). The protocols
to load this drug were the following: to a aqueous suspension containing 1.0 mg of naked calcium
carbonate nanocrystals was added a quantity of the drug from stock solution in order to obtain two
final concentration of NVP-BEZ235 of 1 µM and 100 µM, followed by stirring of the mixtures for 24 h
at room temperature. Unbound drug was removed by dialysis against deionized water for 5 h using
membrane with MWCO 3500. After washing and centrifugation, drug loading was calculated in the
supernatant by LC-MS/MS by the following formula:
%loading = 100 − ([NVP-BEZ235] prior loading − [NVP-BEZ235] after loading)/[NVP-BEZ235] prior loading
The concentration of NVP-BEZ235 prior loading was 100 µM and the concentration after loading
was calculated from the area of the chromatographic peak of the analyte by LC-MS/MS.
3.5. Cell Culture
HUT78 cell line was cultured in RPMI-1640 supplemented with 10% fetal bovine serum
(FBS, heat inactivated at 56 ◦C for 30 min), 2 mM L-glutamine and 100 U/mL penicillin and streptomycin,
under normal conditions (37 ◦C, 5% CO2 under humidified atmosphere) in suspension flasks.
3.6. Cell Proliferation Assay
T-cell lymphoma line was treated with free NVP-BEZ235 (1.0 µM) and encapsulated NVP-BEZ235
(1.0 µM equivalent) at different times. Cell proliferation was evaluated by MTT assay, which measures
the conversion of a tetrazolium compound into formazan by a mitochondrial dehydrogenase enzyme
in live cells. Briefly, 15 µL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was
added to each well for 4 h at 37 ◦C. A solubilizing solution was added for 1 h, and the absorbance
was then measured at 550/630 nm using a plate reader (DAS, Rome, Italy). The relative cell viability
was expressed as a percentage of the untreated control wells. Each data point is the average of three
independent determinations. A p values of <0.05 were considered statistically significant.
3.7. Confocal Laser-Scanning Fluorescence Microscopy (CLSM)
Laser scanning confocal microscopy was performed on a Zeiss LSM700 (Zeiss, Goettingen,
Germany) confocal microscope equipped with an Axio Observer Z1 (Zeiss) inverted microscope
using an objective 100×, with 1.46 numerical aperture oil immersion lens for imaging. Laser beams
with 405 and 488 nm excitation wavelengths were used for Hoechst dye and labelled CaCO3 NCs,
respectively. Cancer cell lines (5× 104) were seeded onto 35 mm glass bottom Petri Dish and incubated
over-night. The cells were incubated with the fluorescent CaCO3 NCs for 5 h in the dark in a humidified
incubator at 37 ◦C, 5% CO2, and 95% relative humidity. The cells were then rinsed with PBS and fixed
with glutaraldehyde 0.25%. All samples were stained with Hoechst 33342 (0.2 µM) for 5 min to check
the nuclei morphology. The images were examined under confocal microscope.
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3.8. Western Blot Analysis
After drug treatments, the cell lines were harvested and lysed using the Mammalian
Cell Extraction Kit (BioVision, Milpitas, CA, USA) following the manufacturer’s instructions.
Proteins (100 µg/lane) were electrophoresed on 4–20% SDS-polyacrylamide gradient gels and
transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA). Membranes
were immunoblotted with the following primary antibodies: total AKT, p-AKT (ser 473), total m-TOR,
p-m-TOR (ser 2448) and caspase-3 (Asp175). All of the above-mentioned antibodies were diluted
1:1000 and purchased from Cell Signaling Technology (Danvers, MA, USA). Then, the membranes were
incubated with species-specific horseradish peroxidase- (HRP-) conjugated secondary antibody (1:500)
from Cell Signaling Technology. Blots were developed using SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL, USA). Images were acquired by Chemidoc XRS.
3.9. Preparation of Standard Solutions
Individual stock solutions of analyte (NVP-BEZ235) and IS (BKM120) were prepared in DMSO to
yield the final concentration of 1 mg/mL. Further dilutions of NVP-BEZ235 were prepared in blank
cell lysate to yield the calibration samples at 1.00, 5.00, 10.0, 50.0 and 100 µM. Independently prepared
NVP-BEZ235 stock solutions at 2.5, 25 and 75 µM were used as low concentration quality control
(LQC), medium concentration quality control (MQC) and high concentration quality control (HQC)
samples, respectively. QC samples were prepared as for calibration standards. 1.0 mg/mL stock
solution of BKM120 was further diluted with acetonitrile (ACN) and added to each calibration sample
to get a 1.0 µg/mL final concentration. Calibration samples, QC samples and IS working solution were
aliquoted and stored at −20 ◦C.
3.10. Sample Preparation of Cell Lysates
3.10.1. Extraction of the Cytosolic Fraction
HUT78 cancer cells were individually incubated with a solution 100 µM free NVP-BEZ235
and encapsulated NVP-BEZ235 100 µM equivalent (preparation reported above) at 37 ◦C for 2, 5,
12 and 24 h. Cultured medium was removed and cells were twice washed with ice-cold acid PBS
(phosphate buffered saline, pH 5.0), scarpered, counted and centrifuged. Each cell aliquot (1 × 106 cells)
was lysed by 25 µL of hypotonic buffer (pH 8, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA,
250 mM sucrose, 0.1 mM PMSF, containing protease inhibitor cocktail), added of IS (final concentration
1 µg/mL) and acetonitrile (25 µL), thermostatted at 95 ◦C for 5 min and centrifuged at 20,817× g for
30 min. The supernatants were dried, reconstituted with 25 µL of mobile phase and injected into the
LC-MS/MS instrument.
3.10.2. Extraction of the Vesicular Fraction
The pellets were suspended in a solution of IS (final concentration 1 µg/mL) and tert-butylmethyl
ether (TBME) (25 µL). The suspension was mixed and centrifuged for 5 min at 20,817× g.
The supernatants were dried, reconstituted with 25 µL of mobile phase and injected into the
LC-MS/MS instrument.
3.11. LC-MS/MS Method for the Quantification of NVP-BEZ235 in Cell Lysates
The quantitative analyses were carried out on an Agilent 1200 liquid chromatograph
(Agilent Technologies, Milan, Italy) consisting of a binary pump, an autosampler and a thermostated
column compartment. An Agilent 6410 triple quadrupole-mass spectrometer (Agilent Technologies)
with an electrospray ionization source operating in positive mode was used for detection (LC-ESI-QqQ).
Flow injection analyses of the analyte and IS were performed to optimize the fragmentor and source
parameters, which were: gas temperature 350 ◦C, gas flow 10 L/min, nebulizer 32 psi, capillary
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voltage 4500 V, fragmentor 135 V. In order to determine the characteristic mass fragments for
multiple reaction monitoring (MRM) analysis, the product spectra of NVP-BEZ235 and IS were
recorded in full scan mode by varying the offset voltage between 10 and 45 eV. The optimal
collision energy value was 45 eV. The quantitative analyses were carried out using selected reaction
monitoring (SRM) following the reactions: m/z 470.4→ 443.3 and m/z 411.3→ 367.3 as quantifiers
for NVP-BEZ235 and IS, respectively; m/z 470.4 → 454.3 and m/z 411.3 → 307.2 as qualifiers for
NVP-BEZ235 and IS, respectively. Mass spectrometry chromatograms were acquired and analyzed
using Agilent MassHunter Qualitative Analyses Version B.01.04 data processing software. The analyses
were performed on a Poroshell 120 (50 × 3.0 mm I.D., 2.7 µm) with a mobile phase composed of
acetonitrile:water:formic acid 95:5:0.1 (v/v/v) at a flow rate of 0.5 mL/min. The injection volume
was 5 µL.
3.12. LC-MS/MS Method Validation
The LC-MS/MS method developed was validated for sensitivity, specificity, linearity, accuracy,
precision, recovery, matrix effect and stability. The method validation details are reported in
Appendix A.
3.13. Statistical Analysis
Statistical differences between controls and drug-treated cells were determined by one-way
ANOVA (Sidak). p-values < 0.05 were considered statistically significant. Data were analyzed using
the Stata 8.2/SE package (StataCorp LP, College Station, TX, USA).
4. Conclusions
It is well established that drug tolerance is one of the key challenges for dual PI3K–mTOR
inhibitors as NVP-BEZ235, which explains the slow progress of research and development of these
inhibitors. Currently, only eleven new dual PI3K–mTOR inhibitors, including NVP-BEZ235, are being
evaluated actively in the clinical stage, is currently in phase I/II clinical trials for advanced solid tumors
(ClinicaTrials.gov, U.S. National Institutes of Health, Bethesda, MD, USA: http://clinicaltrials.gov),
but none has been approved by the FDA. Although significant therapeutic effects against cancer have
been demonstrated, NVP-BEZ235 have shown significant toxicity, including stomatitis, noninfectious
pneumonitis, rash, hyperglycemia, and immunosuppression. Encapsulation strategy offers a potential
approach for enhancing the solubility of NVP-BEZ235 improving its bioavailability and suggests the
potential use of this formulation for oral administration. Oral administration would allow outpatient
treatment, improving quality of life and reducing treatment costs.
Cytosolic delivery strategies could contribute to simplify the entry or export of various cargo
that are insufficiently permeable to plasma membrane. In this work we proposed an engineered
system, based on CaCO3, to deliver NVP-BEZ235. Because of their central role in the initiation
and progression of tumors, blockade of the mTOR and PI3K signaling pathways has emerged as
a compelling target for the development of novel drug formulations for maximal therapeutic efficacy
in many tumors. Taken together, it appears that dual PI3K/mTOR inhibitors, such as NVP-BEZ235,
are required. Because of its intrinsic chemical hydrophobicity, NVP-BEZ235 is poorly tolerable from
patients and negatively influenced the clinical studies [27]. Its toxicity profile causes high percentage of
adverse events leading to frequent discontinuation treatments. Despite these problems NVP-BEZ235
remains an attractive agent. Therefore, in order to overcome its chemical limitations, it is necessary
to either reduce the administered dose or combining the efficacy of this molecule with other drugs
for a synergic action. In view of its potentiality, and on the other side of its limitations, we focused
this work on finding a nanotechnological strategy to achieve higher efficacy of the drug toward cancer
cells, decreasing drug concentration and increasing drug penetration. Hence, we developed at first
a promising payload drug delivery system based on CaCO3 NCs that improved the water solubility
of NVP-BEZ235 making it immediately available to cell machinery. Furthermore, a new highly
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sensitive analytical method methods have been used to determine, qualitatively or quantitatively,
whether NVP-BEZ235 has successfully traversed the cell membrane. The obtained nano-formulation
has a cytosolic localization more efficient (almost 30%) than the free drug as demonstrated in the
quantification analysis of NVP-BEZ235 in the intracellular fraction. This result is affected in a cytotoxic
effect almost 50 times higher than free drug at the same nominal concentration, in T-cell lymphoma
line, as well as in the phosphorylation of proteins involved in the mTOR pathway, as demonstrated
in the western blot analysis. These overall results show that the fabrication of loaded NVP-BEZ235
CaCO3 nanocrystals is a promising drug delivery system able to improve the pharmacokinetics of
this drug.
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Appendix A. LC-MS/MS Method Validation
• Detection and quantification limits (sensitivity)
Limit of quantification (LOQ) was defined as the concentration at which the quantifier transition
of BEZ235 yielded a signal to noise ratio (S/N) of 10 and it was 1 µM in cell lysate. Limit of detection
(LOD) in cell lysate was estimate based on 5:1 S/N and it was 0.5 µM.
• Specificity
Typical SRM chromatograms of BEZ235 and IS in cell lysate showed no interfering peaks from
endogenous substances at the retention time of BEZ235 and IS. The chromatograms of blank cell lysate
also had no interfering peaks at the retention times of BEZ235 and IS. The specificity results indicate
that the method is highly selective for BEZ235 analysis.
• Calibration curve and Linearity
Calibration curves for BEZ235 were performed in cell lysates (1 to 100 µM). Five replicates were
used to establish the linear calibration equation (y = mx + c) and analyzed using the ratio of analyte
peak area over IS peak area after quantitative integration by Mass Hunter software. Linearity was
measured as the coefficient of determination (R2) for five calibration replicates. The acceptance criteria
for each back-calculated standard concentration were ±15% deviation from the nominal value except
at LOQ, which was set at ±20%. Linearity was excellent in the range 1–100 µM with corresponding
coefficient of determination R2 > 0.998.
• Accuracy and precision
Intra-day accuracy and precision were assessed from five replicates of LOQ and QC concentration
levels (low LQC, middle MQC and high HQC). Inter-day accuracy and precision were assessed on
three triplicates for five-day analysis of the three QC concentration levels. Accuracy of the method was
calculated as percent deviation based on the difference between the mean concentration found and the
nominal concentration. The percent deviation should be within 15% of the actual value, except at the
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LOQ, where it should not deviate by more than 20%. Precision was evaluated as percentage coefficient
of variation (%CV) of the mean concentration found. The precision determined at each concentration
level should not exceed 15% of the CV, except for the LOQ, where it should not exceed 20% of the CV.
The accuracy and precision data for cell lysate. The intra-day accuracy showed percent deviation
ranging from −1.19 to 4.22% with a %CV from 0.88 to 4.65%. The inter-day accuracy and precision
showed percent of deviation ranged from to −3.80 to 8.50% with a %CV from 2.09 to 8.78. Since the
accuracy and precision values were found within the acceptance limits, these results suggested that
the method is accurate and precise.
• Recovery
The extraction recovery of BEZ235 was determined at the LQC, MQC and HQC levels by
comparing the peak areas of BEZ235 extracted from spiked cell lysate samples prepared by spiking
BEZ235 in blank cell lysate with the corresponding concentration of authentic standard solutions.
Experiments were performed in five replicates. The extent of recovery should be consistent, precise and
reproducible. The recovery of extraction of BEZ235 from cell lysate was >82%.
• Matrix effect
The matrix effect was evaluated by determining the matrix factor (MF) and the IS-normalized MF
from cell lysate. The determination was performed at the LQC, MQC and HQC levels in triplicate.
The MF of BEZ235 was calculated by comparing the peak area of BEZ235 extracted from samples
prepared by spiking BEZ235 in cell lysate with the corresponding concentration of the authentic
solution of BEZ235 prepared in mobile phase. The MF of IS was determined and calculated in a similar
manner. The IS-normalized MF is the ratio between the MF of BEZ235 and that of IS. The %CV of the
IS-normalized MF from blank cell lysate should not exceed 15%. The %CV of IS-normalized MF in
cell lysate was <10%. The %CV < 15% suggests that ion suppression or enhancement from cell lysate
matrix is negligible in the assay.
• Stability
Stock solutions of BEZ235 and IS were checked for short-term stability at room temperature,
autosampler stability at 10 ◦C, freeze-thaw cycles at −20 ◦C and long-term stability at −70 ◦C.
Stability results in cell lysate were evaluated by measuring the area ratio response (analyte/IS)
of stability samples against freshly prepared comparison standards at the same concentration.
The solutions were considered stable if the deviation was within ±10%. Tests for bench top at room
temperature, autosampler stability at 10 ◦C, freeze-thaw cycles at −20 ◦C and long-term stability at
−70 ◦C were performed using six replicates. The stability samples were quantified against freshly
prepared comparison standards at the same concentration. Stability data were acceptable if the %CV
of the replicate determinations did not exceed 15% and the mean accuracy value was within ±15% of
the nominal value. Short-term stability analysis for bench top at room temperature and autosampler at
10 ◦C showed %CV lower than 9.8% and 4.2%, respectively, indicating that BEZ235 is stable under
experimental conditions. %CV after three freeze-thaw cycles at −20 ◦C and for long-term at −70 ◦C
were >90% and >50%, respectively, indicating low stability of BEZ235 in these conditions.
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